Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue
_blank

Advertising Opportunities

Click Here

Email A Friend Back to Archived News


Samaritan Breast Cancer Diagnostic Issued U.S. Patent


Wednesday, May 16, 2007

Unique Advantages:

  • Faster Prognosis With Breast Cancer Diagnosis Taking 1-7 Days Compared to the Traditional 3-Weeks
  • Determines Breast Cancer Tumor Aggressiveness and Likelihood of Cancer Metastasis Efficaciously

Las Vegas, NV -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it has received a notice that the United States patent, Title: Peripheral-Type Benzodiazepine Receptor: A tool for detection, diagnosis, prognosis, and treatment of cancer was formally allowed on April 9, 2007. U.S. Patent Application Serial Number: 09/047,652.

Samaritan's diagnostic kit is comprised of antibodies against PBR suitable for use in detecting the presence of an aggressive breast cancer tumor. This patent's claims are related to a biopsy test. Samaritan has also filed another application for a blood test against the same marker.

The patent has been awarded to Georgetown University and is exclusively licensed to Samaritan.

See peer reviewed journal publications:

http://www.samaritanpharma.com/publications_and_patents.asp

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures!"

Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease, Acute Coronary Disease, Cancer, HIV, and Hepatitis-C. Samaritan has collaborates its "oral" HIV viral-entry inhibitor for "HIV drug resistance" with Pharmaplaz, Ireland, and plans to advance SP-01A to Phase III. Samaritan has three drug candidates in various stages of IND development, it's building upon its issued IND for Caprospinol, SP-233, to treat memory loss in Alzheimer's disease patients; evaluating the use of SP-1000 for acute coronary disease patients; and the use of SP-10T1 as an "oral treatment" for Hepatitis-C. In addition, Samaritan has acquired the marketing and sales rights to sell nine revenue-generating products in Greece and/or various Eastern European countries.

Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

Contact: Samaritan Pharmaceuticals, Inc.; Richard Brown; (702) 735-7001; RichardBrown@SamaritanPharma.com.



Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free